Cohero Health, a NYC-based digital health company developing connected health tools and technologies to empower respiratory patients and improve care through smart mobile devices, has raised $9 million in Series A funding. The funding round is led by Three Leaf Ventures, an affiliate of the Broe Group, with continuing participation from Zaffre Investments, the investment arm of Blue Cross Blue Shield of Massachusetts, and BioAdvance. To date, the company has raised $11 million in total funding.
New investors include GIS Strategic Ventures, Heitkamp & Thumann Group, and P5 Health Ventures. The company plans to use the latest round to scale its commercial business development efforts, robust clinical trial program, and evolve BreatheSmart, the company’s comprehensive connected platform.
Founded in 2012, Cohero Health’s sensor-based technology and engaging platform improves medication adherence and care coordination between patients and their care providers. By using an integrated, connected health model, Cohera’s solutions enables tracking of controller medication, rescue medication and discern lung function in real-time.
“We started Cohero Health with the goal of empowering pulmonary patients to engage in their care,” said Melissa Manice, PhD, co-founder and CEO. “This investment will sustain this mission, transforming respiratory care for patients and the many stakeholders that support the respiratory community.”
The company’s connected device, BreatheSmart actively engages and empowers respiratory patients by tracking medication adherence and measuring lung function available on iOS and Android. Its FDA cleared mobile spirometer measures lung function; mobile applications engage patients, and generate custom reminders and reward compliance; and web applications access custom data via HIPAA-compliant servers.
Clinical validation has demonstrated the platform’s viability, achieving medication adherence rates 2.5 times those of standard of care, along with drastic reductions in emergency room visits. In addition to improving care through digital tools, the company is building the world’s largest data set of respiratory patient demographics, medication utilization, symptoms, exacerbations, pulmonary function, medical history, outcomes and costs. With this data, Cohero Health is introducing a new paradigm of respiratory medicine powered by predictive analytics and personalized treatment.
The company has established new strategic partnerships with ImagineCare, developed by Dartmouth Hitchcock as well as H&T Presspart, with whom they have debuted the eMDI, a fully integrated metered dose inhaler that tracks and communicates medication utilization.
To date, Cohero Health has successfully deployed its platform across more than 25 commercial partnerships including major healthcare systems, hospital systems, payers, pharmaceutical manufacturers, pharmacy benefit managers, and other strategic partners, representing over 1 million pediatric and adult asthma, COPD, and cystic fibrosis patients.